GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate superiority of single treatment of
GSK1358820 (hereinafter, referred to as BOTOX®) over placebo in terms of the efficacy of
treatment with BOTOX® 50 U in each axilla (100 U in total for each patient) as intradermal
injections based on gravimetric assessment (measurement of spontaneous axillary sweat
production) for axillary hyperhidrosis.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA